RxSight, Inc. (RXST) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 80.44M USD | Liabilities, Current |
| Cash and equivalents | 13.35M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 18.52M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 37.12M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $80.44M | $13.35M | (m) | $18.52M | $37.12M | (m) |
| 2026-03-31 | (m) | $27.38M | $17.57M | (m) | $22.44M | $34.87M | (m) |
| 2025-12-31 | (m) | $26.25M | $19.95M | (m) | $23.38M | $31.56M | (m) |
| 2025-09-30 | (m) | $22.29M | $29.63M | (m) | $24.15M | $28.95M | (m) |
| 2025-06-30 | (m) | $20.38M | $40.35M | (m) | $28.06M | $25.06M | (m) |
| 2025-03-31 | (m) | $22.74M | $28.00M | (m) | $30.96M | $23.57M | (m) |
| 2024-12-31 | (m) | $25.88M | $16.71M | (m) | $30.05M | $22.01M | (m) |
| 2024-09-30 | (m) | $22.64M | $16.72M | (m) | $25.37M | $21.67M | (m) |
| 2024-06-30 | (m) | $19.62M | $24.45M | (m) | $25.72M | $19.44M | (m) |
| 2024-03-31 | (m) | $18.33M | $32.65M | (m) | $21.55M | $18.70M | (m) |
| 2023-12-31 | (m) | $20.90M | $9.69M | (m) | $20.28M | $17.42M | (m) |
| 2023-09-30 | (m) | $18.94M | $9.86M | (m) | $15.24M | $18.92M | (m) |
| 2023-06-30 | (m) | $16.57M | $8.75M | (m) | $13.29M | $17.95M | (m) |
| 2023-03-31 | (m) | $14.88M | $11.01M | (m) | $12.67M | $18.07M | (m) |
| 2022-12-31 | (m) | $17.24M | $11.83M | (m) | $10.96M | $14.84M | (m) |
| 2022-09-30 | (m) | $16.37M | $8.91M | (m) | $9.02M | $15.34M | (m) |
| 2022-06-30 | (m) | $13.00M | $24.00M | (m) | $6.88M | $11.62M | (m) |
| 2022-03-31 | (m) | $10.66M | $24.13M | (m) | $5.63M | $8.49M | (m) |
| 2021-12-31 | (m) | $11.08M | $24.36M | (m) | $4.86M | $8.03M | (m) |
| 2021-09-30 | (m) | $9.18M | $68.28M | (m) | $4.36M | $9.44M | (m) |
| 2021-06-30 | (m) | $11.10M | $41.73M | (m) | $3.94M | $8.54M | (m) |
| 2020-12-31 | (m) | $11.60M | $13.99M | (m) | $2.87M | $8.29M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |